JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Arbutus Biopharma Corp

Cerrado

3.31 -0.9

Resumen

Variación precio

24h

Actual

Mínimo

3.29

Máximo

3.39

Métricas clave

By Trading Economics

Ingresos

-12M

-25M

Ventas

190K

1.8M

Margen de beneficios

-1,390.363

Empleados

44

EBITDA

-12M

-24M

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-40M

601M

Apertura anterior

4.21

Cierre anterior

3.31

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Arbutus Biopharma Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 23:57 UTC

Adquisiciones, fusiones, absorciones

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Adquisiciones, fusiones, absorciones

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Charlas de Mercado

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Charlas de Mercado

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Ganancias

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Charlas de Mercado
Ganancias

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Ganancias

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Ganancias

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Ganancias

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Ganancias

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparación entre iguales

Cambio de precio

Arbutus Biopharma Corp previsión

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.255 / 3.365Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.